(Q40007577)

English

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

S Shamimi-Noori

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

W-S Yeow

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

M F Ziauddin

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

H Xin

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

T L N Tran

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

J Xie

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

A Loehfelm

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

P Patel

8

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

J Yang

9

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

D S Schrump

10

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

B L Fang

11

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

D M Nguyen

12

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

29 February 2008

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Cancer Gene Therapy

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

356-370

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Safety and antitumor activity of recombinant soluble Apo2 ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Apoptosis control by death and decoy receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Apo2L/TRAIL and its death and decoy receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Targeting death receptors in cancer with Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Caspase structure, proteolytic substrates, and function during apoptotic cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Caspase activation: the induced-proximity model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

A unified model for apical caspase activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

The mitochondrial death/life regulator in apoptosis and necrosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Mechanisms of cytochrome c release by proapoptotic BCL-2 family members

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Two CD95 (APO-1/Fas) signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Toxic proteins released from mitochondria in cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Defining characteristics of Types I and II apoptotic cells in response to TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Bcl-2 overexpression enhances tumor-specific T-cell survival

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Anti-liver cancer activity of TNF-related apoptosis-inducing ligand gene and its bystander effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

Intravascular adenoviral agents in cancer patients: lessons from clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

21 January 2018

BID-dependent and BID-independent pathways for BAX insertion into mitochondria

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

7 January 2021

based on heuristic

inferred from DOI database lookup

The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell d

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7701120

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.CGT.7701120

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40007577&oldid=2203313729"